Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor natural killer therapy CTH-401 for ovarian cancer, and to expand its pipeline to include other diseases. Cartherics CEO Alan Trounson told BioWorld that the funds raised will take Cartherics through to mid-2026, and the phase I Australian trial in ovarian cancer will begin in the fourth quarter of 2025. Read More
The gene encoding methylthioadenosine phosphorylase (MTAP) is expressed in normal tissues but 10 to 15% of tumors present deletions of MTAP expression that lead to accumulation of its metabolite 5-methylthioadenosine (MTA). Previous research has shown that selective inhibition of protein arginine methyltransferase 5 (PRMT5) in the presence of MTA may be considered a potential therapeutic strategy for the treatment of MTAP-deleted cancer. Read More
Ege University scientists and their collaborators have detailed the preclinical characterization of a novel DNA vaccine encoding the SRS13 protein being developed for the prevention of chronic toxoplasmosis. Read More
Alentis Therapeutics AG has obtained IND clearance from the FDA for ALE.P02, an anti-Claudin-1 (CLDN1) antibody-drug conjugate (ADC) with a tubulin inhibitor payload. Read More
Scientists at University of California and University of Illinois have disclosed compounds acting as estrogen receptor β (ER-β; ESR2) ligands. Read More
Researchers from Splisense Ltd. and affiliated organizations recently reported preclinical data for SPL-84, an inhaled antisense oligonucleotide drug candidate being developed for the treatment of patients with cystic fibrosis carrying the 3849 +10 kb C-to-T (3849) mutation. Read More
Researchers at Baylor College of Medicine and Deliver Therapeutics Inc. have synthesized protein kinase inhibitors reported to be useful for the treatment of cancer and psoriasis. Read More
Recursion Pharmaceuticals Inc. has gained IND clearance from the FDA for a phase I/II trial of REC-1245 in a biomarker-enriched patient population, including patients with solid tumors and lymphoma. The trial is expected to begin in the fourth quarter of this year. Read More
Humanwell Healthcare (Group) Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis. Read More
Inmagene LLC presented preclinical data for the novel noncovalent reversible Bruton tyrosine kinase (BTK) inhibitor IMG-004, which is in phase I development for autoimmune diseases. Read More
Astrazeneca AB has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon unit coupled to an androgen receptor (AR) targeting moiety via a linker acting as AR degradation inducers reported to be useful for the treatment of cancer. Read More
The development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has significantly improved the therapeutic scenario for CF patients in the past decade. However, around 10% of patients harboring nonsense and splice-site mutations are nonresponsive to CFTR modulators. Read More
Thirtyfivebio Ltd. has described G protein-coupled receptor GPR35 antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory, cardiovascular, gastrointestinal and immunological disorders. Read More
Additional early-stage research and drug discovery news in brief, from: Be Biopharma, Cereno Scientific, Deepcure, Harmony Biosciences, Ocean Biomedical, Satellos Bioscience, Scineuro Pharmaceuticals, Silexion Therapeutics. Read More
